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Elaine L. Hill, Lauren Miller, Heather Link, Katelyn Carey, Neil S. Seligman University of Rochester Medical Center, Rochester, NY OBJECTIVE: Buprenorphine is now commonly used as the first-line opioid pharmacotherapy for pregnant women with opioid use disorder (OUD), but little is known regarding effects of treatment setting on outcomes. The objective of this study is to determine whether there are differences in treatment characteristics and neonatal outcomes between pregnant women receiving buprenorphine in private practice (PP) versus outpatient treatment programs (OTP). STUDY DESIGN: Retrospective cohort study of pregnant women receiving buprenorphine at an urban, academic medical center from 2011 to 2017. Women were divided into two groups by OUD treatment setting: PP versus OTP. Unadjusted and adjusted analyses were performed to assess differences in treatment and neonatal outcomes. Comparison of means was performed using T-test. Hepatitis C status, smoking, maternal age, race/ethnicity, parity, gestational diabetes, pre-eclampsia, dose at delivery and use of buprenorphine at conception were included in the adjusted analyses. RESULTS: 107 pregnant women were included of which 70 (65.4%) received buprenorphine at a PP and 37 (34.6%) received buprenorphine at an OTP. Women treated at a PP were less likely to have been receiving buprenorphine prior to conception than those treated at an OTP (63% versus 83%, p <0.05; Table 1 ). Buprenorphine dose during first and second trimesters were similar, however women in the PP group received approximately 4mg more buprenorphine in the third trimester and at delivery than women in the OTP group (p<0.01). These differences reflect the tendency for women treated at an OTP to be on lower doses at delivery compared to the first or second trimester. There was no significant difference in neonatal outcomes with the exception of head circumference which was larger in the OTP group even after adjusting for confounding (0.97 cm, adj. p¼ 0.047; Table 2 ). CONCLUSION: There were several differences in treatment characteristics between pregnant women receiving buprenorphine for OUD at a PP versus OTP including higher delivery dose and a lower likelihood of dose reduction during pregnancy. However, neonatal outcomes were similar with the exception of a small difference in head circumference. The reason for the difference in treatment characteristics requires further study. OBJECTIVE: Although spontaneous abortion (SAB) is common, recurrent SAB is far less common, with only 2-3% of women having 2 consecutive SABs and <1% having 3 or more consecutive SABs. Although the incidence of subsequent SAB has been well-defined in women with a history of recurrent pregnancy loss (RPL), prior studies evaluating perinatal outcomes in subsequent pregnancies have shown mixed results. In this study, we aimed to evaluate perinatal outcomes in our patient population in women with a history of RPL. STUDY DESIGN: Retrospective cohort study of singleton, non-anomalous gestations at 20 weeks who delivered at our academic institution. The exposed group was defined as women with a history of 2 consecutive SABs at <12 weeks. These women were compared to women with a history of 1 SAB at <12 weeks. The primary outcome was preterm birth at <37 weeks. Secondary outcomes included fetal growth restriction (FGR), gestational diabetes (GDM), hypertensive disorders of pregnancy, indication for preterm birth, gestational age (GA) at delivery, fetal demise, cesarean delivery, and a composite of neonatal complications (Apgar <5 at 5 minutes, perinatal death, and NICU admission). Multivariable logistic regression was performed to adjust for confounders, with the following variables considered in the model: maternal age, race, BMI, payor status, hypertension, and diabetes. RESULTS: Of 17,670 women included, 235 (1.3%) had a history of 2 consecutive SABs. Compared to women with a history of 1 SAB, women with RPL were not more likely to have a preterm birth (Table) . However, these women were more likely to have FGR (6% vs 2.4%,p¼<0.001, AOR 2.1, 95% CI: 1.1-3.8) and gestational DM (12.3% vs 6.6%, p¼<0.001, AOR 1.59, 95% CI: 1.04-2.43). All other maternal and neonatal outcomes were not statistically different. CONCLUSION: Women with a history of 2 consecutive SABs have an increased incidence of FGR and GDM in a subsequent pregnancy. Monitoring for these conditions in women with 2 consecutive SABs may be warranted. Georgetown University School of Medicine, Washington, DC OBJECTIVE: To identify the blood loss measurement technique that best predicts need for red blood cell (RBC) transfusion after cesarean delivery (CD) and to define the amount of blood, by technique, that predicts RBC transfusion. STUDY DESIGN: This was a retrospective review of a quality improvement initiative of all women with singleton pregnancies who underwent CD at >¼34 weeks' gestation between July 1, 2017 and June 30, 2018 at MedStar Washington Hospital Center. Women were eligible to have blood loss measured by visually estimated blood loss (EBL), gravimetric quantitative blood loss (QBL), Gauss Surgical's Triton ipad application (TBL) and a 24-hour postoperative complete blood count evaluation. Women with multifetal gestation, hypertensive disease and magnesium or anti-hypertensive treatment were excluded. The primary outcome was RBC transfusion. Receiveroperating characteristic curves with area under the curves (AUC) for RBC transfusion by blood loss measurement techniques were created by EBL, QBL and TBL. Blood loss volumes that best predict RBC transfusion were estimated according to blood loss measurement techniques. The secondary outcome included blood loss volumes that best predict RBC transfusion as estimated by measurement technique. We performed a secondary analysis after excluding women with preoperative hemoglobin <10 g/dL. RESULTS: Of the 444 women meeting inclusion criteria, 21 (4.7%) received RBC transfusion. Women who received RBC transfusion compared to women without RBC transfusion were more likely to have higher gravidity, intravenous fluid infusion, EBL, QBL, TBL, and lower preoperative hemoglobin levels (all P <.05). (Figure) . However, there were no statistical differences among blood loss measurement techniques (P¼.22). Blood loss
